整蛋白型肠内营养制剂改善脓毒症肠损伤代谢紊乱的机制研究

黄彪, 张正涛, 左丹, 杨洋, 罗仁杰, 赵乙汜, 徐昉

PDF(1971 KB)
PDF(1971 KB)
重庆医科大学学报 ›› 2024, Vol. 49 ›› Issue (04) : 444-450. DOI: 10.13406/j.cnki.cyxb.003474
基础研究

整蛋白型肠内营养制剂改善脓毒症肠损伤代谢紊乱的机制研究

作者信息 +

Mechanism of intact-protein enteral nutrition formula improving intestinal injury and metabolic disorders in sepsis

Author information +
History +

摘要

目的 利用代谢组学方法研究脓毒症中整蛋白营养制剂引起的代谢紊乱,为脓毒症的临床治疗提供了新的理论和实验基础。 方法 8~12周龄雄性小鼠随机分为3组:假手术组(Sham组)、脓毒症组(CLP组)和脓毒症+整蛋白组(CLP+IPEN组),每组6只小鼠。CLP组采用盲肠结扎和穿刺诱导脓毒症,而Sham组仅行剖腹手术,未行结扎穿刺。CLP+IPEN组术后接受额外的整蛋白肠内营养制剂。每天监测体质量变化7 d,并在建模和喂养3 d后采集样本。染色观察回肠组织病理学变化,实时荧光定量聚合酶链式反应(quantitative real-time PCR)检测不同目的基因mRNA的表达。根据特定的标准,筛选整蛋白营养制剂治疗脓毒症的差异代谢物。 结果 CLP组与CLP+IPEN组进行比较,发现有15种差异代谢物。在CLP+IPEN组中,3-甲基-1,3,5-戊三醇(dimethyl 3-hydroxy-3-methylpentane-1,5-dioate)、丙二酸(malonic acid)、苯酰胺(l-Serine,n-methoxycarbonyl-methyl ester)等5种代谢物的含量比CLP组有所增加(P<0.05)。在整个实验过程中,3组小鼠的体质量均逐渐减轻,其中CLP组在4 d的体质量减轻最为明显(P<0.05)。这表明,整蛋白营养制剂可以减轻脓毒症小鼠的体质量减轻。CLP+IPEN组的Chiu评分明显低于CLP组(P<0.05),提示肠黏膜损伤明显减少。CLP组和Sham组中闭合蛋白(occludin)、紧密连接蛋白1(zonula occludens-1,ZO-1)和结肠黏蛋白(recombinant mucin 2,MUC2)的表达均升高,提示脓毒症导致肠道屏障功能受损。与CLP组相比,CLP+IPEN组中Occludin、ZO-1和MUC2的表达明显降低(P<0.05)。 结论 本研究通过代谢组学方法深入研究整蛋白营养制剂中脓毒症引起的代谢紊乱。整蛋白肠内营养制剂可以通过调节亚油酸代谢、不饱和脂肪酸生物合成、脂肪酸生物合成和细胞色素P450物质的代谢来改善脓毒症相关肠道损伤的代谢紊乱。此外,这些制剂在增强肠道屏障功能、减轻小鼠体质量减轻和减轻肠道损伤严重程度方面具有潜力,从而为增强脓毒症治疗功效奠定了基础。

Abstract

Objective To investigate the metabolic disorders induced by intact-protein enteral nutrition formula in sepsis through metabolomics methods,and to provide new theoretical and experimental bases for the clinical treatment of sepsis. Methods Male mice,aged 8-12 weeks,were randomly divided into sham-operation group(Sham group),sepsis group(CLP),and sepsis+intact-protein enteral nutrition group(CLP+IPEN group),with 6 mice in each group. The mice in the CLP group were treated with cecal ligation and puncture to induce sepsis,while those in the Sham group were given laparotomy alone without ligation and puncture. The mice in the CLP+IPEN group received additional intact-protein enteral nutrition formula after surgery. Daily weight changes were monitored for 7 days,and samples were collected after 3 days of modeling and feeding. Staining was used to observe the histopathological changes of the ileum,and quantitative real-time PCR was used to measure the expression of different proteins. Differentially expressed metabolites in the treatment of sepsis with intact-protein enteral nutrition formula were identified based on specific criteria. Results There were 15 differentially expressed metabolites between the CLP group and the CLP+IPEN group. Compared with the CLP group,the CLP+IPEN group had significant increases in the content of five metabolites including dimethyl 3-hydroxy-3-methylpentane-1,5-dioate,malonic acid,and L-Serine,N-(methoxycarbonyl)-methyl ester(P<0.05). Throughout the experiment,all three groups of mice showed a gradual reduction in body weight,and the CLP group showed the most significant weight loss on day 4(P<0.05),suggesting that intact-protein enteral nutrition formula could alleviate weight loss in mice with sepsis. The CLP+IPEN group had a significantly lower Chiu score than the CLP group(P<0.05),indicating a notable reduction in intestinal mucosal injury. Both the CLP group and the Sham group had significant increases in the expression of occludin,zonula occludens-1(ZO-1),and MUC2,suggesting that sepsis caused impairment of intestinal barrier function. Compared with the CLP group,the CLP+IPEN group had significant reductions in the expression of occludin,ZO-1,and MUC2(P<0.05). Conclusion This study investigates the metabolic disorders induced by intact-protein enteral nutrition formula in sepsis through metabolomics methods,and the results show that intact-protein enteral nutrition formula can alleviate metabolic disorders in sepsis-related intestinal injury by regulating linoleic acid metabolism,biosynthesis of unsaturated fatty acids,biosynthesis of fatty acids,and metabolism of cytochrome P450 substances. In addition,such formulas have the potential in enhancing intestinal barrier function,mitigating weight loss in mice,and reducing the severity of intestinal injury,thereby laying a foundation for strengthening the efficacy of sepsis treatment.

关键词

整蛋白型 / 脓毒症 / 肠损伤 / 代谢紊乱

Key words

intact-protein / sepsis / intestinal injury / metabolic disorders

中图分类号

R151

引用本文

导出引用
黄彪 , 张正涛 , 左丹 , . 整蛋白型肠内营养制剂改善脓毒症肠损伤代谢紊乱的机制研究. 重庆医科大学学报. 2024, 49(04): 444-450 https://doi.org/10.13406/j.cnki.cyxb.003474
Huang Biao, Zhang Zhengtao, Zuo Dan, et al. Mechanism of intact-protein enteral nutrition formula improving intestinal injury and metabolic disorders in sepsis[J]. Journal of Chongqing Medical University. 2024, 49(04): 444-450 https://doi.org/10.13406/j.cnki.cyxb.003474

参考文献

1
Wei JX Jiang HL Chen XH. Endothelial cell metabolism in sePsis[J]. World J Emerg Med202314(1):10-16.
2
孙啸宇,陆宗庆,张 金,等. 《拯救脓毒症运动:脓毒症与脓毒性休克治疗国际指南(2021)》摘译与解读[J]. 中国中西医结合急救杂志202128(6):645-652.
Sun XY Lu ZQ Zhang J,et al. InterPretation of Surviving SePsis CamPaign:international guidelines for management of sePsis and sePtic shock 2021[J]. Chin J Integr Tradit West Med Intensive Crit Care202128(6):645-652.
3
Fleischmann-Struzek C Mellhammar L Rose N,et al. Incidence and mortality of hosPital- and ICU-treated sePsis:results from an uPdated and exPanded systematic review and meta-analysis[J]. Intensive Care Med202046(8):1552-1562.
4
Yao LN Zhang L Zhou CJ. Analysis of Prognostic risk factors of sePsis Patients in intensive care unit based on data analysis[J]. J Healthc Eng20222022:3746640.
5
Wang GL Ma FF Xie KM,et al. Liensinine alleviates mouse intestinal injury induced by sePsis through inhibition of oxidative stress,inflammation,and cell aPoPtosis[J]. Int ImmunoPharmacol2024127:111335.
6
Tian WZ Yue Q Fei W,et al. PE (0:0/14:0),an endogenous metabolite of the gut microbiota,exerts Protective effects against sePsis-induced intestinal injury by modulating the AHR/CYP1A1 Pathway[J]. Clin Sci2023137(22):1753-1769.
7
Zhao J Pan X Hao D,et al. Causal associations of gut microbiota and metabolites on sePsis:a two-samPle Mendelian randomization study[J]. Front Immunol202314:1190230.
8
Tyszko M Lemańska-Perek A Śmiechowicz J,et al. Citrulline,intestinal fatty acid-binding Protein and the acute gastrointestinal injury score as Predictors of gastrointestinal failure in Patients with sePsis and sePtic shock[J]. Nutrients202315(9):2100.
9
Lubbers T de Haan JJ Hadfoune M,et al. LiPid-enriched enteral nutrition controls the inflammatory resPonse in murine Gram-negative sePsis[J]. Crit Care Med201038(10):1996-2002.
10
刘承宇,陈丽如,朱明炜. 重症患者早期肠内营养的研究进展[J]. 中华临床营养杂志202230(3):161-166.
Liu CY Chen LR Zhu MW. Research Progress on early enteral nutrition in critically ill Patients[J]. Chin J Clin Nutr202230(3):161-166.
11
Rittirsch D Huber-Lang MS Flierl MA,et al. Immunodesign of exPerimental sePsis by cecal ligation and Puncture[J]. Nat Protoc20094(1):31-36.
12
王龙海. 百里醌通过激活SIRT1/STAT3通路对脓毒症所致大鼠肝损伤和糖代谢紊乱的保护作用[J]. 重庆医科大学学报202146(12):1473-1478.
Wang LH. Protective effects of thymoquinone on sePsis-induced liver injury and glucose metabolism disorder in rats by activating SIRT1/STAT3 Pathway[J]. J Chongqing Med Univ202146(12):1473-1478.
13
Madushani RWMA Patel V Loftus T,et al. Early biomarker signatures in surgical sePsis[J]. J Surg Res2022277:372-383.
14
Cao T Ni R Ding WM,et al. Nicotinamide mononucleotide as a theraPeutic agent to alleviate multi-organ failure in sePsis[J]. J Transl Med202321(1):883.
15
Quan RZ Chen CY Yan W,et al. BAFF blockade attenuates inflammatory resPonses and intestinal barrier dysfunction in a murine endotoxemia model[J]. Front Immunol202011:570920.
16
Xu H You J He WQ,et al. Dynamic changes in the migratory microbial components of colon tissue during different periods of sepsis in an LPS-induced rat model[J]. Front Cell Infect Microbiol202313:1330087.
17
Song WY Huang J Li Y,et al. The role of TLR4/MyD88/NF-κB in the Protective effect of ulinastatin on the intestinal mucosal barrier in mice with sePsis[J]. BMC Anesthesiol202323(1):414.
18
Hua ZJ Wang YQ Chen WP,et al. Emodin protects against intestinal dysfunction and enhances survival in rat model of septic peritonitis through anti-inflammatory actions[J]. Immun Inflamm Dis202311(8): e942.
19
Xie SH Yang T Wang ZF,et al. Astragaloside IV attenuates sePsis-induced intestinal barrier dysfunction via suPPressing RhoA/NLRP3 inflammasome signaling[J]. Int ImmunoPharmacol202078:106066.
20
王丹妮,华黎电,潘志国,等. 体重指数对脓毒症患者预后的影响:基于大型临床数据库MIMIC-Ⅲ的回顾性分析[J]. 解放军医学杂志202146(2):129-135.
Wang DN Hua LD Pan ZG,et al. The imPact of body mass index on the Prognosis in sePsis Patients:a retrosPective analysis on account of the large clinical database MIMIC-Ⅲ[J]. Med J Chin PeoPle’s Liberation Army202146(2):129-135.
21
吕艳超,李兴华,刘 颖. 益生菌联合整蛋白型肠内营养辅助治疗脓毒血症的疗效及对肠道和免疫功能的影响[J]. 中国现代医学杂志202030(24):61-65.
YC Li XH Liu Y. Effect of Probiotics combined with enteral nutrition with a nonelemental diet on sePsis and intestinal and immune function[J]. China J Mod Med202030(24):61-65.
22
Duan YT Huang JJ Sun MJ,et al. Poria cocos Polysaccharide imProves intestinal barrier function and maintains intestinal homeostasis in mice[J]. Int J Biol Macromol2023249:125953.
23
刘慧恒,王隽笙,林锦洲,等. 降钙素原通过影响磷酸化蛋白激酶Cα、闭合蛋白表达损害脓毒症大鼠肠黏膜屏障功能[J]. 创伤与急诊电子杂志202311(1):1-9.
Liu HH Wang JS Lin JZ,et al. Procalcitonin imPairs intestinal mucosal barrier by decreasing occludin exPression via activation of P-PKCα in sePtic rats[J]. J Trauma Emerg Electron Version202311(1):1-9.
24
刘 莉,谢 胜,刘礼剑,等. 胃食管反流病患者血浆代谢组学研究及临床观察[J]. 广西大学学报(自然科学版)202247(1):254-261.
Liu L Xie S Liu LJ,et al. Plasma metabolomics study and clinical observation in Patients with gastroesoPhageal reflux disease[J]. J Guangxi Univ Nat Sci Ed202247(1):254-261.
25
KirkuP SE Cheng Z Elmes M,et al. Polyunsaturated fatty acids modulate Prostaglandin synthesis by ovine amnion cells in vitro [J]. ReProduction2010140(6):943-951.

基金

重庆市科卫联合医学科研资助项目(2022MSXM020)
重庆市大足区科技发展资助项目(DZKJ2023JSYJ-KWXM1014)

评论

PDF(1971 KB)

Accesses

Citation

Detail

段落导航
相关文章

/